ArticleAlcohol, clinical & experimental research2026
Short-Term Risk Stratification in Alcohol-Associated Hepatitis: Small HDL Particles and Inflammation Vulnerability Index Values Improve Model for End-Stage Liver Disease.
Article in Alcohol, clinical & experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlcohol-associated hepatitis (AH) has high short-term mortality, whereas current prognostic models mainly reflect liver and renal dysfunction. The Metabolic Vulnerability Index (MVX) is a nuclear magnetic resonance-derived score comprising the Inflammation Vulnerability Index (IVX; small high-density lipoprotein particles [S-HDL-P] and GlycA) and the Metabolic Malnutrition Index (MMX). We evaluated whether MVX, IVX, and IVX components improve 90-day mortality prediction beyond Model for End-Stage Liver Disease (MELD) in AH.
methodsSerum samples from 196 patients with AH, 169 heavy-drinking controls, and 351 healthy controls were analyzed by nuclear magnetic resonance spectroscopy. The primary outcome was 90-day AH-related mortality. Biomarkers were modeled continuously after standardization within the AH cohort; S-HDL-P was modeled per 1 SD decrease. Cox models were adjusted for MELD, age, sex, white blood cell count, and baseline antibiotic or corticosteroid use. Model performance was assessed using Akaike information criterion (AIC), likelihood-ratio testing, and Harrell's C-statistic.
resultsAmong patients with AH, 30 AH-related deaths occurred within 90 days (15.3%). IVX and MVX were highest in AH cases and increased with AH severity, whereas MMX did not consistently differentiate severity. Lower S-HDL-P was independently associated with 90-day mortality in fully adjusted models (HR, 1.84; 95% CI, 1.01-3.35; p = 0.045), whereas GlycA was not (HR, 0.86; 95% CI, 0.54-1.37; p = 0.527). Adding S-HDL-P improved fully adjusted MELD-based model fit (AIC, 298.97 vs. 301.46; LR p = 0.034; C-statistic, 0.741 vs. 0.729). IVX showed supportive improvement in model fit and discrimination (AIC, 299.81; LR p = 0.056; C-statistic, 0.749). Continuous MELD interaction analyses supported risk separation for S-HDL-P (LR χ
conclusionsLower S-HDL-P appears to be the principal short-term prognostic component within the IVX domain in AH. S-HDL-P and IVX may refine MELD-based 90-day risk stratification, pending external validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.